Claris Ventures
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Claris Ventures.
Key people at Claris Ventures.
Claris Ventures is a venture capital firm specializing in early-stage biopharma investments focused on life sciences innovations with strong scientific foundations. Their mission is to support scientists and innovators addressing unmet clinical needs in areas such as rare diseases, oncology, and immunology by providing capital, expertise, and hands-on support to accelerate clinical development and value creation based on clinical evidence. The firm plays a significant role in the European biotech startup ecosystem by enabling early clinical validation and fostering partnerships or M&A opportunities with major pharmaceutical companies[1][2][3].
Founded in 2019 and based in Torino, Italy, Claris Ventures was established to leverage scientific excellence emerging from the Italian and broader European research ecosystem. Key partners include managing and investment professionals with deep expertise in biotech and healthcare. The firm has evolved by launching dedicated funds such as Claris Biotech I and recently Claris Biotech II, the latter targeting €100 million to continue backing early-stage biotech startups with promising therapeutic programs. Institutional investors like CDP Venture Capital and the European Investment Fund (EIF) support these funds, reflecting confidence in Claris Ventures’ scouting and portfolio-building capabilities[3][4][6].
Claris Ventures rides the growing trend of translating scientific breakthroughs into biotech startups that address critical health challenges. The timing is favorable due to increased EU support for innovation, rising demand for novel therapies in oncology, immunology, and rare diseases, and a maturing European biotech ecosystem. By focusing on early clinical validation, Claris Ventures helps bridge the gap between academic research and commercial drug development, influencing the broader ecosystem by enabling startups to reach partnering or acquisition stages with large pharmaceutical companies[1][4].
Claris Ventures is poised to expand its impact with the new Claris Biotech II fund, aiming to deepen its portfolio and accelerate biotech innovation in Europe. Future trends shaping their journey include advances in precision medicine, immunotherapies, and digital health integration in drug development. Their influence is likely to grow as they continue to catalyze early-stage biotech companies, fostering collaborations that could lead to breakthrough therapies and enhanced patient outcomes across Europe and beyond[4].
In summary, Claris Ventures stands out as a specialized, science-driven venture capital firm that plays a crucial role in nurturing early-stage biotech startups, leveraging strong institutional support and deep sector expertise to drive innovation in life sciences.
Key people at Claris Ventures.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2023 | Repron Therapeutics | $2.0M Seed | — | — |
| Oct 1, 2022 | Sibylla Biotech | $23.0M Series A | — | Marianne Bjørdal, 3B Future Health Ventures (Helsinn Investment Fund), Seroba Life Sciences |
